C3a and C5a complement components have shown to act as key players supporting the development of cancer cells where C3aR/C5aR signaling on the surface of T lymphocytes acts as an immune checkpoint inhibiting the production of IL-10 in effector T lymphocytes37. This evidence concerns the gene C5 and cancer.